Search results for "cost-effectivene"

showing 10 items of 76 documents

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

2016

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cas…

RNA virusesDecision AnalysisPhysiologyEconomicsCost-Benefit AnalysisSocial Scienceslcsh:MedicineBlood DonorsHepacivirusmedicine.disease_causeBiochemistryHepatitis0302 clinical medicineImmune Physiology030212 general & internal medicineChroniclcsh:SciencePathology and laboratory medicinehealth care economics and organizationsMultidisciplinaryImmune System ProteinsCost–benefit analysisHepatitis C virusLiver DiseaseCost-effectiveness analysisMedical microbiologyHepatitis CHCV AntibodyInfectious DiseasesVirusesEngineering and TechnologyBlood Banks030211 gastroenterology & hepatologyPathogensInfectionManagement EngineeringResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyHepatitis C virusImmunologyCost-Effectiveness AnalysisImmunoblottingChronic Liver Disease and CirrhosisMolecular Probe TechniquesAntibody levelResearch and Analysis MethodsMicrobiologyAntibodies03 medical and health sciencesChronic hepatitisHepatitis - CClinical ResearchInternal medicineparasitic diseasesmedicineHumansImmunoassaysMolecular Biology TechniquesSensitivity analysesMolecular BiologyMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryDecision Treeslcsh:RHepatitis C antibodyOrganismsViral pathogensProteinsHepatitis C ChronicHepatitis C AntibodiesHepatitis virusesEconomic AnalysisMicrobial pathogensHealth CareEmerging Infectious DiseasesCost Effectiveness ResearchHealth Care FacilitiesImmunologyImmunologic Techniqueslcsh:QbusinessDigestive Diseases
researchProduct

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

2015

Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…

AdultMalesafetymedicine.medical_specialtyCarcinoma HepatocellularCost effectivenesschemoembolisationCost-Benefit AnalysisAntineoplastic AgentsTreatment failureDrug CostsEthiodized OilInternal medicinemedicineOverall survivalHumansPharmacology (medical)Chemoembolization Therapeuticcost-effectivenessAgedRetrospective StudiesPharmacologyAged 80 and overDrug CarriersDrug eluting beadsPublic health insurancebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisMicrospheres3. Good healthSurgerySurvival RateTreatment OutcomeMedian timeDoxorubicinHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleProspective payment systembusinessIdarubicin
researchProduct

Cost effectiveness of aortic valve therapies: a systematic review of the literature

2022

Background: Systematic review on the cost effectiveness of transcatheter aortic valve implantation (TAVI) to standard aortic valve replacement and medical management in high-risk elderly patients with severe aortic stenosis. Evidenced based systematic reviews are the core methodologies in health economics for evaluating cost effectiveness and medical effectiveness. Clarity and transparency of these reports can help to provide health care interventions accurately and reliably. Methods: In accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses, a systematic review on current literature for cost-effectiveness of TAVI, standard aortic valve replacement, and medical m…

Aortic valvemedicine.medical_specialtyCost effectivenessmedicine.medical_treatmentSettore MED/42 - Igiene Generale E ApplicataValve replacementAortic valve replacementsystematic reviewmedicinelcsh:R5-920Transcatheter aortic valve implantationcost effectivenessbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseSurgeryQuality-adjusted life yearStenosisSystematic reviewmedicine.anatomical_structureAortic stenosis; Transcatheter aortic valve implantation; Cost effectiveness; Clinical effectiveness; Systematic reviewbusinesslcsh:Medicine (General)Incremental cost-effectiveness ratio
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct

Photobiomodulation and myofascial temporomandibular disorder: Systematic review and meta-analysis followed by cost-effectiveness analysis

2021

Background Photobiomodulation (PBM) is a non-invasive and non-pharmacological treatment, which, has shown beneficial results in the treatment of temporomandibular disorders (TMD) related pain. This systematic review and meta-analysis study aimed to evaluate the efficacy of photobiomodulation in the treatment of myofascial pain associated with (TMD by analyzing randomized clinical trials published from 2007 to February 2019. The secondary objective of the study was to perform a cost-effectiveness analysis of TMD treatment with photobiomodulation in patients with myofascial pain. Material and methods International databases were used: Pubmed, Medline and Web of Science; the initial search rai…

medicine.medical_specialtybusiness.industryTemporomandibular disorderMEDLINEOrthodonticsCost-effectiveness analysisReviewPlacebolaw.inventionQuality of evidenceRandomized controlled trialLaser therapylawMeta-analysisPhysical therapyMedicinebusinessGeneral DentistryUNESCO:CIENCIAS MÉDICASJournal of Clinical and Experimental Dentistry
researchProduct

Análisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente

2014

Introducción: En España, con una prevalencia del 2,5%, la hepatitis C (VHC) se asocia a una elevada morbi-mortalidad. El tratamiento combinado de telaprevir y peginterferon/ribavirina ([T/PR]) es eficaz en pacientes con VHC-G1. El objetivo primario de este estudio fue evaluar la relación coste-utilidad (RCUI) de [T/PR] versus peginterferon alfa 2a/ribavirina ([PR]) en pacientes naïve VHC-G1, según el grado de fibrosis y bajo la perspectiva del sistema sanitario español. Metodología: La eficacia y la incidencia de efectos adversos (EAs) se obtuvieron de los estudios ADVANCE y OPTIMIZE. La estimación de los costes de monitorización, de manejo de EAs y de la enfermedad por estados de salud (€,…

; Genotype 1lcsh:RRibavirinalcsh:Medicinelcsh:RS1-441Genotype 1Hepatitis CTelaprevirGenotipo 1lcsh:Pharmacy and materia medicaCoste-utilidadCost-effectivenessPeginterferon alfa 2aRibavirinehealth care economics and organizationsFarmacia Hospitalaria
researchProduct

A comprehensive fracture prevention strategy in older adults : The European union geriatric medicine society (EUGMS) statement

2016

Published also in Aging Clinical and Experimental Research, Vol.28, No.4, WOS: 000379034800030 Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) - European society for clinical and economic aspects …

GerontologyAgingStatement (logic)Cost effectivenessOsteoporosisPoison controlMedicine (miscellaneous)postmenopausal womenPosition statementSuicide preventionOccupational safety and healthlaw.inventionFractures Bonezoledronic acid0302 clinical medicineRandomized controlled trialBone DensitylawSecondary PreventionFallNutrition and DieteticMedicine030212 general & internal medicinerisk-factorsComputingMilieux_MISCELLANEOUSmedia_commonGeriatricsAged 80 and overHip fractureNutrition and Dietetics[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyosteoporotic fractures[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyAccidental Fallfall induced injuriesFragility fracture3. Good healthPrimary Prevention[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemrandomized controlled-trialsFracture preventionbone-mineral densityFallsHumanmedicine.drugmedicine.medical_specialtyeducationhip-fracture030209 endocrinology & metabolism[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyArticle03 medical and health sciencespharmacological-treatmentsmedia_common.cataloged_instanceHumansEuropean UnionEuropean unioncost-effectivenessAgedFragility fracturePostmenopausal womenbusiness.industryPublic healthPreventionOsteoporosimedicine.disease[SDV.AEN] Life Sciences [q-bio]/Food and NutritionZoledronic acidGeriatrics3121 General medicine internal medicine and other clinical medicineddc:618.97Physical therapyOsteoporosisAccidental FallsFalls; fragility fracture; older people; position statement; prevention; Accidental Falls; Aged; Aged 80 and over; European Union; Fractures Bone; Geriatrics; Humans; Osteoporosis; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyOlder peopleGeriatrics and GerontologybusinessOlder people[SDV.AEN]Life Sciences [q-bio]/Food and NutritionGerontologyGeriatric
researchProduct

Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patients

2019

Objective: Atrial fibrillation (AF) is a major cause for recurrent stroke, has severe impact on a patient's health and imposes a high economic burden for society. Current guidelines recommend 24 h ECG monitoring (standard-of-care, SoC) to detect AF after stroke to reduce the risk of future events. However, paroxysmal AF (PAF) is difficult to detect within this period as it occurs infrequently and unpredictably. In a randomized controlled trial (Find-AF(RANDOMISED)), prolonged and enhanced Holter ECG monitoring (EPM) revealed a significantly higher detection rate of AF compared to SoC, although its cost-effectiveness has not yet been investigated. Methods: Based on the data of FIND-AF(RANDOM…

AdultMalemedicine.medical_specialtymacromolecular substancesCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyGUIDELINESTHERAPYBrain Ischemia03 medical and health sciences0302 clinical medicineRecurrent strokeInternal medicinemedicineMANAGEMENTHumanscardiovascular diseases030212 general & internal medicinequality-adjusted life yearsAcute ischemic strokeStrokeAgedAged 80 and overbusiness.industrycost-benefit analysisAtrial fibrillationGeneral MedicineCost-effectiveness analysisMiddle AgedWirtschaftswissenschaftenmedicine.diseaseAtrial fibrillationstroke3. Good healthQuality-adjusted life yearTRIALSEconomic evaluationATRIAL-FIBRILLATIONCardiologyElectrocardiography AmbulatoryQuality of LifeFemalebusinessHolter monitoringsecondary preventionTASK-FORCE
researchProduct

Cost-effectiveness analysis of sewer mining versus centralized wastewater treatment: Case study of the Arga river basin, Spain

2015

ABSTRACT:In the context of the EU Water Framework Directive, a Cost-Effectiveness Analysis (CEA) was performed to compare centralized and decentralized wastewater treatment strategies aimed to improve the ecological status of a Spanish river. The implementation of several hybrid membrane bioreactors within the urban framework for sewer mining (SM) was compared with the more common wastewater treatment plant enlargement option. The assessment ranked 6 alternatives based on 12 potential scenarios, aimed at narrowing the uncertainty of the CEA. The cost analysis illustrated that SM is the most expensive option regarding both investment and operation and maintenance costs. However, the effectiv…

EngineeringEconomics0208 environmental biotechnologyGeography Planning and DevelopmentDrainage basinContext (language use)02 engineering and technology010501 environmental sciences01 natural sciencesSewer mining0105 earth and related environmental sciencesWater Science and TechnologyHybrid membrane bioreactorgeographygeography.geographical_feature_categorybusiness.industryCost-effectiveness analysisEnvironmental engineeringDecentralized wastewater treatmentCost-effectiveness analysisEnvironmental economicsInvestment (macroeconomics)020801 environmental engineeringWater Framework DirectiveCost analysisSewage treatmentbusinessUrban Water Journal
researchProduct